Katzenberger Rebeccah J, Marengo Matthew S, Wassarman David A
Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706, USA.
J Biol Chem. 2009 Apr 17;284(16):10737-46. doi: 10.1074/jbc.M809506200. Epub 2009 Feb 13.
Alternative pre-mRNA splicing is a major gene expression regulatory mechanism in metazoan organisms. Proteins that bind pre-mRNA elements and control assembly of splicing complexes regulate utilization of pre-mRNA alternative splice sites. To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT). The screen identified 15 proteins that, when knocked down, caused the same change in TAF1 alternative splicing as CPT treatment. However, combined RNA interference and CPT treatment experiments indicated that only a subset of the identified proteins are targets of the CPT-induced signal, suggesting that multiple independent pathways regulate TAF1 alternative splicing. To understand how signals modulate the function of splicing factors, we characterized one of the CPT targets, Tra2 (Transformer-2). CPT was found to down-regulate Tra2 protein levels. CPT-induced Tra2 down-regulation was ATR-dependent and temporally paralleled the change in TAF1 alternative splicing, supporting the conclusion that Tra2 directly regulates TAF1 alternative splicing. Additionally, CPT-induced Tra2 down-regulation occurred independently of new protein synthesis, suggesting a post-translational mechanism. The proteasome inhibitor MG132 reduced CPT-induced Tra2 degradation and TAF1 alternative splicing, and mutation of evolutionarily conserved Tra2 lysine 81, a potential ubiquitin conjugation site, to arginine inhibited CPT-induced Tra2 degradation, supporting a proteasome-dependent alternative splicing mechanism. We conclude that CPT-induced TAF1 alternative splicing occurs through ATR-signaled degradation of a subset of splicing-regulatory proteins.
可变前体mRNA剪接是后生动物中一种主要的基因表达调控机制。结合前体mRNA元件并控制剪接复合体组装的蛋白质,会调节前体mRNA可变剪接位点的利用。为了了解信号通路如何影响这一机制,研究人员在果蝇S2细胞中进行了一项RNA干扰筛选,以鉴定在化疗药物喜树碱(CPT)激活ATR(ATM-RAD3相关)信号通路后,调控TAF1(TBP相关因子1)可变剪接的蛋白质。该筛选鉴定出了15种蛋白质,当它们被敲低时,会导致TAF1可变剪接发生与CPT处理相同的变化。然而,RNA干扰和CPT联合处理实验表明,所鉴定的蛋白质中只有一部分是CPT诱导信号的靶点,这表明多种独立的信号通路调控TAF1可变剪接。为了了解信号如何调节剪接因子的功能,我们对CPT的一个靶点Tra2(Transformer-2)进行了表征。研究发现CPT会下调Tra2蛋白水平。CPT诱导的Tra2下调依赖于ATR,并且在时间上与TAF1可变剪接的变化平行,这支持了Tra2直接调控TAF1可变剪接的结论。此外,CPT诱导的Tra2下调独立于新蛋白质合成发生,提示存在一种翻译后机制。蛋白酶体抑制剂MG132减少了CPT诱导的Tra2降解和TAF1可变剪接,并且将进化保守的Tra2赖氨酸81(一个潜在的泛素结合位点)突变为精氨酸,抑制了CPT诱导的Tra2降解。这支持了一种蛋白酶体依赖性的可变剪接机制。我们得出结论,CPT诱导的TAF1可变剪接是通过ATR信号介导的一部分剪接调节蛋白的降解而发生的。